In high-recurrence-risk hepatocellular carcinoma after curative-intent resection/ablation, updated IMbrave050 data show adjuvant atezolizumab plus bevacizumab did not sustain recurrence-free survival benefit vs active surveillance and overall survival remains immature

In high-recurrence-risk hepatocellular carcinoma after curative-intent resection/ablation, updated IMbrave050 data show adjuvant atezolizumab plus bevacizumab did not sustain recurrence-free survival benefit vs active surveillance and overall survival remains immature - Notícias Vera Health